SAT-091 Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms

Background: Ruxolitinib is a JAK1/2 inhibitor that is FDA approved to treat certain myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). The JAK family kinases are targeted in cancers due to their role in cytokine receptor signal transduction, and are also ke...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Main Authors: Sapre, Manali, Tremblay, Douglas, Leiter, Amanda, Coltoff, Alexander, Geevarghese, Anita, Mascarhenas, John, Gallagher, Emily
Formato: Artigo
Idioma:Inglês
Publicado: Endocrine Society 2019
Assuntos:
Adipose Tissue, Appetite, and Obesity
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552330/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-091
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares